Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.

22 Oct 2008

Biothera initiates second phase of metastatic colorectal cancer trial

Biothera has announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August.

16 Oct 2008

Outlook for Crohn's disease improves due to new therapies

A study led by Mayo Clinic has found that infliximab (Remicade) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

6 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Eli Lilly starts second global phase III trial of investigational Alzheimer's disease compound

Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

2 Oct 2008

New results help predict treatment response in colorectal cancer

Genetic testing can identify a group of patients with advanced colorectal cancer who are likely to survive on average twice as long if treated with the drug cetuximab, late breaking results show.

16 Sep 2008

Merck Serono and Ablynx to jointly develop nanobodies

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx, to co-discover and co-develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR10 million.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Discovery of new genes for inflammatory bowel disease in children

Researchers have discovered two new genes that increase the risk of developing inflammatory bowel disease (IBD) in childhood.

31 Aug 2008

Genmab announces four studies of ofatumumab in chronic lymphocytic leukemia

Genmab A/S announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year.

25 Aug 2008

Amgen announces positive results for Denosumab postmenopausal osteoporosis trial

Amgen has announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis.

27 Jul 2008

New center for protein therapeutics formed by UB pharmaceutical scientists

Pharmaceutical researchers at the University at Buffalo have joined forces with scientists from several of the world's largest pharmaceutical companies to tackle fundamental research questions that need to be answered to advance development of promising protein-based drugs.

15 Jul 2008

Nanotechnology, biomolecules, and light unite to "cook" cancer cells

Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.

9 Jul 2008

Individualized therapies for non-Hodgkin's lymphoma identified with PET

Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)-the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at the Society of Nuclear Medicine's 55th Annual Meeting.

16 Jun 2008

Peregrine Pharmaceuticals awarded two new U.S. patents for targeted anti-aminophospholipid agents

Peregrine Pharmaceuticals, Inc. today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents.

16 Jun 2008

Compugen announces discovery of novel drug targets for cancer antibody therapeutics

Compugen Ltd. announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer.

11 Jun 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Discovery provides hope for patients with pancreatic cancer

This week researchers in the Oregon Health & Science University (OHSU) Oregon Stem Cell Center and the OHSU Digestive Health Center are shining a new ray of hope on patients with pancreatic cancer. They've developed new reagents, or antibodies, that can recognize this often lethal disease. This important discovery may one day lead to earlier detection and treatment.

22 May 2008